7AEI

Studies Towards a Reversible EGFR C797S Triple Mutant Inhibitor Series

Summary for 7AEI

Entry DOI	10.2210/pdb7aei/pdb
Descriptor	Epidermal growth factor receptor, 5-chloranyl-~{N}2-[4-[4-(dimethylamino)piperidin-1-yl]-2-methoxy-5-(1-methylpyrazol-4-yl)phenyl]-~{N}4-(2-dimethylphosphorylphenyl)pyrimidine-2,4-diamine (3 entities in total)
Functional Keywords	egfr, cell cycle
Biological source	Homo sapiens (Human)
Total number of polymer chains	1
Total formula weight	38057.36
Authors	Hargreaves, D. (deposition date: 2020-09-17, release date: 2021-06-02, Last modification date: 2024-05-01)
Primary citation	Floch, N.,Finlay, M.R.V.,Bianco, A.,Bickerton, S.,Colclough, N.,Cross, D.A.,Cuomo, E.M.,Guerot, C.M.,Hargreaves, D.,Martin, M.J.,McKerrecher, D.,O'Neill, D.J.,Orme, J.P.,Rahi, A.,Smith, P.D.,Ward, R.A. Abstract 4451: Evaluation of the therapeutic potential of phosphine oxide pyrazole inhibitors in tumors harboring EGFR C797S mutation Cancer Res., 79:4451-, 2019 Cited by DOI: 10.1158/1538-7445.AM2019-4451 PDB entries with the same primary citation
Experimental method	X-RAY DIFFRACTION (2.65 Å)

Structure validation